80 related articles for article (PubMed ID: 15700398)
1. Tenofovir regimen compared with Combivir.
AIDS Patient Care STDS; 2005 Jan; 19(1):59-60. PubMed ID: 15700398
[No Abstract] [Full Text] [Related]
2. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
Feinberg J
AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
[No Abstract] [Full Text] [Related]
3. Anti-HIV agents. Dueling nukes: AZT + 3TC vs. tenofovir + FTC.
TreatmentUpdate; 2005; 17(5):5-7. PubMed ID: 17225279
[No Abstract] [Full Text] [Related]
4. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Stellbrink HJ; Orkin C; Arribas JR; Compston J; Gerstoft J; Van Wijngaerden E; Lazzarin A; Rizzardini G; Sprenger HG; Lambert J; Sture G; Leather D; Hughes S; Zucchi P; Pearce H;
Clin Infect Dis; 2010 Oct; 51(8):963-72. PubMed ID: 20828304
[TBL] [Abstract][Full Text] [Related]
5. Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada).
Palacios R; Terrón A; Hidalgo A; Rivero A; Santos J;
J Antimicrob Chemother; 2008 Feb; 61(2):462-3. PubMed ID: 18156608
[No Abstract] [Full Text] [Related]
6. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Gutiérrez S; Guillemi S; Jahnke N; Montessori V; Harrigan PR; Montaner JS
Clin Infect Dis; 2008 Feb; 46(3):e28-30. PubMed ID: 18181733
[TBL] [Abstract][Full Text] [Related]
7. Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.
Manosuthi W; Lueangniyomkul A; Mankatitham W; Chimsuntorn S; Tantanathip P; Thongyen S; Suntisuklappon B; Nilkamhang S; Sungkanuparph S
J Infect; 2011 May; 62(5):406-9. PubMed ID: 21382413
[No Abstract] [Full Text] [Related]
8. The art of managing human immunodeficiency virus infection: a balancing act.
Reiss P
Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978
[No Abstract] [Full Text] [Related]
9. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
10. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
Sax PE
AIDS Clin Care; 2005 Jan; 17(1):6-7. PubMed ID: 15717372
[No Abstract] [Full Text] [Related]
11. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
12. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
[No Abstract] [Full Text] [Related]
13. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
[TBL] [Abstract][Full Text] [Related]
14. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Redfield RR; Morrow JS
Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
[No Abstract] [Full Text] [Related]
15. Recent developments in HIV treatment, Part 2.
Boyle BA
AIDS Read; 2005 Jun; 15(6):277-9, 284. PubMed ID: 15962449
[No Abstract] [Full Text] [Related]
16. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Lapadula G; Costarelli S; Quiros-Roldan E; Calabresi A; Izzo I; Carosi G; Torti C
Clin Infect Dis; 2008 Apr; 46(7):1127-9. PubMed ID: 18444839
[No Abstract] [Full Text] [Related]
17. Tenofovir and didanosine: a dangerous liaison.
Waters L; Maitland D; Moyle GJ
AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
[No Abstract] [Full Text] [Related]
18. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
[TBL] [Abstract][Full Text] [Related]
19. Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.
Winston J; Shepp DH
HIV Med; 2006 Oct; 7(7):484-5. PubMed ID: 16925736
[No Abstract] [Full Text] [Related]
20. Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
Gupta Samir K
AIDS Read; 2007 Feb; 17(2):102-3. PubMed ID: 17323509
[No Abstract] [Full Text] [Related]
[Next] [New Search]
